No Flush Niacin (Inositol Hexanicotinate) 800 mg

No Flush Niacin (Inositol Hexanicotinate) 800 mg

Life Extension4.7 (3,746 ratings)
Format:Capsule Quantity: 100 Capsule(s) · 100 servings
Goals
$15.75 $0.15 per serving

Product analysis

67 out of 100

No Flush Niacin (Inositol Hexanicotinate) 800 mg provides a clearly identified niacin preparation at a low cost per serving. The available cardiovascular evidence does not support this preparation for the blood markers considered.

AI assessment of the formula, label and price. How scoring works

Nutrient Quality53

Niacin is clearly identified as inositol hexanicotinate. The quality of the additional inositol-related declarations cannot be confirmed more closely.

Ingredient Transparency88

All listed amounts are disclosed and the niacin preparation is identified. One additional inositol-related form remains unspecified.

Value For Money100

The niacin serving offers good value in the available price comparison. Low cost does not establish usefulness for its intended cardiovascular purpose.

Customer Satisfaction88

Customer feedback is very positive across thousands of ratings. The large review base gives an established picture of satisfaction.

Product Focus0

The available cardiovascular evidence does not support this niacin preparation for the markers considered. The other listed inositol-related ingredients do not establish an additional cardiovascular benefit.

Format
Capsule
Container
100 Capsule(s)
Per serving
$0.15
Customer rating
4.7 · 3,746 ratings
Report analysis

Goals

Heart Health
Impact
Limited evidence
F Ingredient FitF PathwaysF EvidenceF Formulation Logic
Study evidence
Niacin Supportive 105 studies
Cardiovascular Support
Impact
Limited evidence
F Ingredient FitF PathwaysF EvidenceF Formulation Logic
Niacin · 640 mg
Study evidence
Niacin Supportive 136 studies

Ingredients

IngredientAmount per servingScore
Niacin (Inositol Hexanicotinate)
640 mg 73
Inositol Hexanicotinate
800 mg
Inositol (Inositol Hexanicotinate)
160 mg
Adults 18–50
Report overview
C- Active Ingredient Quality & BioavailabilityB Dose, Safety & Label TransparencyA+ Value
A serving provides 640 mg of niacin. The cost per serving is low. The niacin form is Inositol Hexanicotinate. The label describes it as no-flush.
How this ingredient is rated

Active Ingredient Quality & Bioavailability57

The niacin form is Inositol Hexanicotinate.
Niacin Form & Goal Alignment
Inositol hexanicotinate is a no-flush form of niacin.
Precursor Source Quality
The source is inositol hexanicotinate.

Dose, Safety & Label Transparency75

A serving provides 640 mg of niacin. The label states no-flush.
Clarity of Chemical Form
The niacin form is Inositol Hexanicotinate.
Form-Specific Dosage Efficacy
A serving provides 640 mg of niacin.
Flush Risk & Safety Labeling
The label states no-flush for inositol hexanicotinate.

Value100

The cost per serving is low.
Price Per Effective Serving
The cost per serving is low.
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
    Lavigne PM; Karas RH · Journal of the American College of Cardiology · 2013
    Meta-analysis9,959 participants11 studies pooledCardiovascular Support forNiacin
  2. Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
    Saboori S; Yousefi Rad E; Tammam J; Thondre PS; Coe S · The British journal of nutrition · 2024
    Meta-analysis12 studies pooledCardiovascular Support forNiacin
  3. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
    Xie S; Galimberti F; Olmastroni E; Carugo S; Catapano AL; Casula M; META-LIPID Group · Atherosclerosis · 2025
    Meta-analysis145,314 participants147 studies pooledCardiovascular Support forNiacin
  4. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD · Archives of internal medicine · 2000
    Randomized trial173 participantsCardiovascular Support forNiacin
  5. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
    Knopp RH; Alagona P; Davidson M; Goldberg AC; Kafonek SD; Kashyap M; Sprecher D; Superko HR; Jenkins S; Marcovina S · Metabolism: clinical and experimental · 1998
    Randomized trial223 participantsCardiovascular Support forNiacin
  6. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
    Superko HR; McGovern ME; Raul E; Garrett B · The American journal of cardiology · 2004
    Randomized trial180 participantsHeart Health forNiacin
  7. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
    Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ · Journal of the American College of Cardiology · 2010
    Randomized trial315 participantsHeart Health forNiacin
  8. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Thoenes M; Oguchi A; Nagamia S; Vaccari CS; Hammoud R; Umpierrez GE; Khan BV · International journal of clinical practice · 2008
    Randomized trial50 participantsHeart Health forNiacin
  9. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
    Duggal JK; Singh M; Attri N; Singh PP; Ahmed N; Pahwa S; Molnar J; Singh S; Khosla S; Arora R · Journal of cardiovascular pharmacology and therapeutics · 2010
    Meta-analysis5,137 participants7 studies pooledHeart Health forNiacin
  10. Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A · Vascular medicine (London, England) · 2014
    Meta-analysis441 participants7 studies pooledHeart Health forNiacin